Senior Director, Scientific Communications
Latigo Biotherapeutics
Senior Director, Scientific Communications
Latigo Biotherapeutics
Clinical-stage biotech developing Nav1.8 inhibitors
Job Title: Senior Director, Scientific Communications
Position Type: Full Time
Location: Thousand Oaks, CA or San Francisco Bay Area
Company Description:
Latigo Biotherapeutics, Inc. is a biotechnology company focused on discovering and developing the next generation of non-opioid medicines for pain and pain-related syndromes. Our mission is the development of novel therapies that transform the lives of patients. The company is headquartered in Thousand Oaks, CA. At Latigo, we value science, patient-focus, and innovation.
Position Description:
Latigo is seeking an exceptionally talented and experienced Senior Director, Scientific Communications to lead the development and execution of scientific communications strategy across our portfolio of clinical-stage, non-opioid pain programs.
This individual will be responsible for translating emerging clinical and scientific evidence into clear, compelling, and scientifically rigorous communications for healthcare professionals, opinion leaders, and other key stakeholders. The role will lead publication planning, congress strategy, scientific platforms, and development of core scientific materials while partnering closely with Medical Affairs, Clinical Development, Regulatory, and other functions. A successful candidate will bring strong scientific acumen, strategic thinking, exceptional communication skills, and the ability to operate effectively in a fast-paced, highly collaborative environment. This role will report directly to the Vice President, Medical Affairs.
Primary Responsibilities:
Qualifications & Experience:
Travel:
Candidate should be willing to travel approximately 20–30% for internal meetings, scientific congresses, and external scientific engagements.
Clinical-stage biotech developing Nav1.8 inhibitors
Latigo Biotherapeutics develops non-opioid pain medicines by discovering and advancing small-molecule drugs, focusing on Nav1.8 channels in peripheral sensory neurons. By blocking Nav1.8, their therapies aim to stop pain at its source, reducing opioid-related risks like addiction and dizziness. The company uses a genetics-informed discovery engine with AI, machine learning, and structure-based design; LTG-001 targets acute pain and LTG-305 targets chronic pain, both in clinical stages. Its differentiated approach centers on genetically validated pain pathways, strong funding, and experienced leadership, with the goal of delivering safe, effective non-opioid analgesics that address pain at its source.
Explore more opportunities at Latigo Biotherapeutics